

ESTABLISHING A GLOBAL AND DIVERSIFIED BIOPHARMACEUTICAL COMPANY

Strategic Rationale

- The companies share a patient-focused mission to develop therapies that address high, unmet medical needs
- Advances the development of VTS-270 for the treatment of Niemann-Pick Type C1 (NPC1), currently in fully enrolled, global pivotal registration program
- Enhances capabilities, resources and expertise to accelerate development and successfully commercialize VTS-270
- Contributes to Sucampo's goal of building an increasingly diversified, global biopharmaceutical company

Financial Highlights

- Sucampo acquired privately-held Vtesse for a total upfront consideration of \$200 million
- Acquisition to be financed through the issuance of \$30 million of Sucampo common shares and \$170 million in cash on hand
- Contingent earn-out payments consist of mid-single digit to double-digit royalties on global net sales of the product at increasing net sales levels
- No external financing required
- Accretive to Sucampo earnings beginning in 2019

INCREASED FOCUS ON RARE DISEASES WITH HIGH UNMET NEED

About VTS-270

- Well-characterized mixture of 2-hydroxypropyl- β -cyclodextrin (HP β CD) with a specific compositional fingerprint that distinguishes it from other HP β CD mixtures
- Mechanism and intrathecal route of administration directly address the devastating and most commonly fatal neurological disease manifestations
- Pivotal Phase 2b/3 fully-enrolled multi-national study
- Compelling Phase 2 and pre-clinical data with clinically significant benefit as measured by disease-specific outcomes
- US FDA and EMA Orphan designation
- US FDA Breakthrough Therapy designation
- UK Medicines and Healthcare Products Regulatory Agency (MHRA) Promising Innovative Medicine ("PIM") designation
- US FDA Rare Pediatric Disease designation

About Niemann-Pick Disease Type C1 (NPC1)

- Ultra-rare, progressive and fatal disease caused by defects in lipid transformation within the cell
- Onset from infancy into adulthood
- Neurological onset most common outside infantile ages
- Progressive and irreversible neurological manifestations
- Estimated 2,000-3,000 cases globally
- Under- and mis-diagnosed
- NPC results in early death in the vast majority of cases
- Currently no approved treatments for the disease in the U.S.

CLINICAL FOCUS	STAGE OF CLINICAL DEVELOPMENT COMPLETED				
	LEAD COMPOUNDS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Lubiprostone – Pediatric Functional Constipation (6 years – 17 years)					
Lubiprostone – Alternate Formulation					
Lubiprostone – Pediatric Functional Constipation (6 months – 6 years)					
CPP-1X/sulindac Combination Product					
VTS-270					

About Sucampo

- Global biopharmaceutical company that is built on the ongoing pursuit of scientific innovation and an unwavering passion for improving the lives of patients
- **Market Products:** AMITIZA and RESCULA
- **Ticker:** SCMP (NASDAQ)
- **Market Cap*:** \$477 million
- **2016 Revenues:** \$230 million
- **Year Founded:** 1996
- **Employees:** 139
- **Headquarters:** Rockville, MD

About Vtesse

- Privately-held company focused on developing drugs for patients suffering from devastating diseases
- **Year Founded:** 2015
- **Employees:** 10
- **Headquarters:** Gaithersburg, MD